Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

iRGD-guided tamoxifen polymersomes inhibit estrogen receptor transcriptional activity and decrease the number of breast cancer cells with self-renewing capacity.

Diaz Bessone MI, Simón-Gracia L, Scodeller P, Ramirez MLA, Lago Huvelle MA, Soler-Illia GJAA, Simian M.

J Nanobiotechnology. 2019 Dec 7;17(1):120. doi: 10.1186/s12951-019-0553-4.

2.

Peptide-guided nanoparticles for glioblastoma targeting.

Säälik P, Lingasamy P, Toome K, Mastandrea I, Rousso-Noori L, Tobi A, Simón-Gracia L, Hunt H, Paiste P, Kotamraju VR, Bergers G, Asser T, Rätsep T, Ruoslahti E, Bjerkvig R, Friedmann-Morvinski D, Teesalu T.

J Control Release. 2019 Aug 28;308:109-118. doi: 10.1016/j.jconrel.2019.06.018. Epub 2019 Jun 27.

PMID:
31255690
3.

Phage-Display-Derived Peptide Binds to Human CD206 and Modeling Reveals a New Binding Site on the Receptor.

Asciutto EK, Kopanchuk S, Lepland A, Simón-Gracia L, Aleman C, Teesalu T, Scodeller P.

J Phys Chem B. 2019 Mar 7;123(9):1973-1982. doi: 10.1021/acs.jpcb.8b11876. Epub 2019 Feb 27.

PMID:
30768279
4.

Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides.

Simón-Gracia L, Hunt H, Teesalu T.

Molecules. 2018 May 16;23(5). pii: E1190. doi: 10.3390/molecules23051190. Review.

5.

Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice.

Simón-Gracia L, Scodeller P, Fuentes SS, Vallejo VG, Ríos X, San Sebastián E, Sidorenko V, Di Silvio D, Suck M, De Lorenzi F, Rizzo LY, von Stillfried S, Kilk K, Lammers T, Moya SE, Teesalu T.

Oncotarget. 2018 Apr 10;9(27):18682-18697. doi: 10.18632/oncotarget.24588. eCollection 2018 Apr 10.

6.

Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.

Wonder E, Simón-Gracia L, Scodeller P, Majzoub RN, Kotamraju VR, Ewert KK, Teesalu T, Safinya CR.

Biomaterials. 2018 Jun;166:52-63. doi: 10.1016/j.biomaterials.2018.02.052. Epub 2018 Mar 2.

7.

Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide.

Scodeller P, Simón-Gracia L, Kopanchuk S, Tobi A, Kilk K, Säälik P, Kurm K, Squadrito ML, Kotamraju VR, Rinken A, De Palma M, Ruoslahti E, Teesalu T.

Sci Rep. 2017 Nov 7;7(1):14655. doi: 10.1038/s41598-017-14709-x.

8.

Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.

Hunt H, Simón-Gracia L, Tobi A, Kotamraju VR, Sharma S, Nigul M, Sugahara KN, Ruoslahti E, Teesalu T.

J Control Release. 2017 Aug 28;260:142-153. doi: 10.1016/j.jconrel.2017.06.005. Epub 2017 Jun 8.

9.

Hyaluronan-binding peptide for targeting peritoneal carcinomatosis.

Ikemoto H, Lingasamy P, Anton Willmore AM, Hunt H, Kurm K, Tammik O, Scodeller P, Simón-Gracia L, Kotamraju VR, Lowy AM, Sugahara KN, Teesalu T.

Tumour Biol. 2017 May;39(5):1010428317701628. doi: 10.1177/1010428317701628.

10.

iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Simón-Gracia L, Hunt H, Scodeller P, Gaitzsch J, Kotamraju VR, Sugahara KN, Tammik O, Ruoslahti E, Battaglia G, Teesalu T.

Biomaterials. 2016 Oct;104:247-57. doi: 10.1016/j.biomaterials.2016.07.023. Epub 2016 Jul 20.

11.

Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy.

Simón-Gracia L, Hunt H, Scodeller PD, Gaitzsch J, Braun GB, Willmore AM, Ruoslahti E, Battaglia G, Teesalu T.

Mol Cancer Ther. 2016 Apr;15(4):670-9. doi: 10.1158/1535-7163.MCT-15-0713-T. Epub 2016 Feb 15.

12.

Targeted silver nanoparticles for ratiometric cell phenotyping.

Willmore AM, Simón-Gracia L, Toome K, Paiste P, Kotamraju VR, Mölder T, Sugahara KN, Ruoslahti E, Braun GB, Teesalu T.

Nanoscale. 2016 Apr 28;8(17):9096-101. doi: 10.1039/c5nr07928d.

13.

Biocompatible, multifunctional, and well-defined OEG-based dendritic platforms for biomedical applications.

Simón-Gracia L, Pulido D, Sevrin C, Grandfils C, Albericio F, Royo M.

Org Biomol Chem. 2013 Jun 28;11(24):4109-21. doi: 10.1039/c3ob40492g.

PMID:
23673687

Supplemental Content

Loading ...
Support Center